KEYNOTE-522
2020
Pembrolizumab + Chemotherapy in Early Triple-Negative Breast Cancer
In 1,174 patients with stage II–III triple-negative breast cancer, neoadjuvant pembrolizumab + platinum/taxane → AC, then adjuvant pembrolizumab improved pathologic complete response and event-free survival compared with placebo + chemotherapy.
Result
Efficacy: pCR and EFS (co-primary)HR 0.63
Below 1 favours neoadjuvant pembrolizumab + platinum/taxane → AC, then adjuvant pembrolizumab, above 1 favours placebo + chemotherapy.
- Absolute difference
- 9.0 points
The absolute difference is derived from the event rates.
Also reported: pCR 64.8% vs 51.2%. 5-yr OS HR 0.66.
- Subtopic
- TNBC neoadjuvant
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Schmid P, et al. N Engl J Med. 2020;382(9):810-821; Schmid P, et al. N Engl J Med. 2022;386(6):556-567.doi 10.1056/NEJMoa1910549
Discussion & critique
Established the first immunotherapy-containing (neo)adjuvant regimen in early TNBC. Long-term immune-related toxicity is a real cost in a curative-intent setting.